This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a randomised, open-label, parallel-group, 8-week comparison trial carried out in 34 centres. The method of randomisation was not reported. Patients were followed for 8 weeks and clinical examinations were conducted at screening, at randomisation and at the end of the study. Loss to follow-up was not reported.
Analysis of effectiveness
The analysis of the clinical study was based on intention to treat. The primary health outcome was the percentage change from baseline in low-density lipoprotein (LDL) after 8 weeks of treatment. Secondary health outcomes were the changes in total cholesterol, triglycerides and high-density lipoprotein (HDL) levels. The comparability of the groups was not reported.
Effectiveness results
The percentage change from baseline in LDL after 8 weeks was: -38.2 (range: -28.2 to -48.2) for atorvastatin 10 mg, -18.9 (range: -4.9 to -32.9) for pravastatin 10 mg, -28.2 (range: -16.2 to -40.2) for simvastatin 10 mg, Changes in total cholesterol, triglycerides and HDL levels were: -28.0, -12.5, and 5.5 for atorvastatin 10 mg, -13.1, 2.9, and 9.9 for pravastatin 10 mg, -20.9, -11.5, and 6.8 for simvastatin 10 mg, 
Clinical conclusions
The analysis of the effectiveness of the drug regimens indicated that atorvastatin (10, 20, and 40 mg) was statistically more effective then the milligram-equivalent dosages of fluvastatin, lovastatin, pravastatin, and simvastatin. At 80 mg/day, atorvastatin reduced LDL by 54.3% and only lovastatin 40 mg twice/day (47.7%) was not statistically different.
Measure of benefits used in the economic analysis
The benefit measure used in the economic analysis was the monthly decrease in levels of LDL, as derived from the effectiveness analysis.
Direct costs
Discounting was not relevant because costs occurred over a period of 8 weeks. Unit costs and the quantities of resources used were not reported. The cost/resource boundary was not reported. Only the acquisition costs of the drugs were included in the analysis and were based on actual data, derived from average wholesale prices in 1999. The dates of the resource data gathering were not reported in the study.
Statistical analysis of costs
No statistical analysis of costs was conducted.
Indirect Costs
No indirect costs were included.
Currency

US dollars ($).
Sensitivity analysis
To assess the possible variability in data, univariate sensitivity analysis was conducted on values of LDL reductions (by the range reported). Cost estimates were also varied to find out threshold values at which results of the analysis would change.
Estimated benefits used in the economic analysis
Please refer to the effectiveness results reported earlier.
Cost results
The monthly and yearly costs were:
$56.40 and $686 for atorvastatin 10 mg,
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Copyright © When the drugs' LDL-reducing effect was set at the minimum value of the range reported, fluvastatin 20 and 40 mg were slightly more cost-effective than atorvastatin. When the maximum value of the range of efficacy was used, atorvastatin remained the most cost-effective drug. Finally, for the other drugs to be as cost-effective as atorvastatin, the reductions in acquisition costs would have to be 16% for fluvastatin ($73), 25% for lovastatin ($221), 27% for pravastatin ($203), and 47% for simvastatin ($652).
Authors' conclusions
Atorvastatin was the most cost-effective strategy for lowering LDL levels in patients with hypercholesterolaemia. The only other drug dose with an annual cost per LDL reduction less than $20 was fluvastatin 40 mg, but it only reduced LDL by 23%.
CRD COMMENTARY -Selection of comparators
The drug therapies were chosen because they represented five commercially available HMG-CoA reductase inhibitors, as reported in the primary study from which the effectiveness evidence was derived. However, the authors highlighted that recently introduced drug regimens, based on higher dosages of fluvastatin and simvastatin and on cerivastatin, were not included in the study. You, as a user of this database, should consider whether they represent widely used drug therapies in your own setting.
Validity of estimate of measure of effectiveness
The analysis of effectiveness was likely to be valid given the use of randomisation. Many details, such as comparability across study groups and the dates during which data on effectiveness were gathered, were not reported because the results of the trial were mainly published elsewhere. However, for some patient groups the sample size was quite small and power calculations were not reported, thus weakening the validity of the effectiveness results.
Validity of estimate of measure of benefit
The benefit measure was derived directly from the effectiveness analysis. The authors noted that LDL reduction was used as a surrogate marker for mortality reduction, which represented the main objective of the drug therapies. However, LDL reduction was widely used as a short-term treatment goal and also recommended by the National Cholesterol Education Program expert panel in the USA.
Validity of estimate of costs
The perspective of the study was not clearly reported and only drug acquisition costs were included in the analysis and, as pointed out by the authors, these prices may not reflect true costs to individuals or to institutions. Costs for the treatment of adverse events were not considered relevant, since the rate of adverse events did not differ between the agents studied. Estimates of cost and quantities of resources used were treated deterministically and no statistical analyses were conducted. The dates during which the resource use data were collected were not reported.
